SYNAIRGEN PLC LS-01
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquart… Read more
SYNAIRGEN PLC LS-01 (OMY) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SYNAIRGEN PLC LS-01 (OMY) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SYNAIRGEN PLC LS-01 - Net Assets Trend (None–None)
This chart illustrates how SYNAIRGEN PLC LS-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SYNAIRGEN PLC LS-01 (None–None)
The table below shows the annual net assets of SYNAIRGEN PLC LS-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SYNAIRGEN PLC LS-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SYNAIRGEN PLC LS-01 Competitors by Market Cap
The table below lists competitors of SYNAIRGEN PLC LS-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Transkon Jaya Pt
JK:TRJA
|
$1.22 Million |
|
Westmount Energy Limited
OTCQB:WMELF
|
$1.22 Million |
|
QURATE RETAIL INC. QVC B
F:LB3C
|
$1.22 Million |
|
Cloudbreak Discovery Plc
PINK:CDBDF
|
$1.22 Million |
|
Dinero Ventures Ltd
V:DNO
|
$1.22 Million |
|
RomReal Limited
OL:ROM
|
$1.22 Million |
|
AERCAP HOLD
BE:R1D
|
$1.22 Million |
|
WORKDAY-A
MU:W7D
|
$1.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SYNAIRGEN PLC LS-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SYNAIRGEN PLC LS-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SYNAIRGEN PLC LS-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SYNAIRGEN PLC LS-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SYNAIRGEN PLC LS-01 (OMY) | €- | N/A | N/A | $1.22 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |